Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Race Oncology Ltd. has discovered that bisantrene, a compound they are developing for cancer treatment, consists of three photoisomers with varying biological activities. The company has developed processes to ensure only the pure active (E,E)-bisantrene isomer is administered to patients, and they have filed three patent applications to protect this innovation. The granting of a composition of matter patent would secure exclusive rights to the chemical structure of (E,E)-bisantrene for 20 years, which is highly valuable in the pharmaceutical industry.
More about Race Oncology Ltd.
Race Oncology Ltd. operates in the pharmaceutical industry, focusing on the development of cancer treatment drugs. Their primary product involves the use of bisantrene, a compound with anticancer properties, and they are working on innovative methods to enhance its efficacy.
Average Trading Volume: 169,438
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$448.4M
See more insights into RAC stock on TipRanks’ Stock Analysis page.